Episode from the podcastTalking Precision Medicine

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

Released Friday, 12th April 2024

Good episode? Give it some love!

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

Friday, 12th April 2024

Good episode? Give it some love!

Rate Episode

In this episode Genialis CEO Rafael Rosengarten sat down with Dr. Carolina Haefliger, head of translational medicine at Debiopharm, the privately held Swiss biopharma company focused on oncology drug development. They talked about de-risking promising new cancer drugs, and what it takes from the science to the team to the technologies.

Episode 35 links:

Rate

Get this podcast via API

From The Podcast

Talking Precision Medicine

Welcome to the Talking Precision Medicine podcast. In this series, we sit down with experts on the application of AI and big data analytics in the drug discovery space. Our guests are innovators, business decision makers and thought leaders at the intersection of data and therapeutics. We discuss the promise, practice, challenges, and myths of AI in precision medicine. This show is brought to you by Genialis, and Rafael, our CEO, is your host.

Join Podchaser to...

Rate podcasts and episodes
Follow podcasts and creators
Create podcast and episode lists
& much more

Episode Tags

Do you host or manage this podcast?
Claim and edit this page to your liking.

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

The Science and Art of De-risking Cancer Drug Development | Talking Precision Medicine #35

From The Podcast

Talking Precision Medicine

Join Podchaser to...

Episode Tags

Unlock more with Podchaser Pro